Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan. (PubMed, J Med Econ) - Sep 9, 2026 - "Scenario analyses were performed using MAIC-based comparisons versus teclistamab and idecabtagene vicleucel (ide-cel). Limitations include reliance on the clinical opinion of a single hematology expert for Japanese clinical practice patterns, extrapolation beyond observed trial follow-up, and inherent constraints of MAIC due to the lack of head-to-head trials. From the healthcare payer perspective, elranatamab was cost-effective versus PCT in the base case and scenario analyses, with ICERs consistently below commonly accepted thresholds in Japan; contingent on the unanchored MAIC and long-term extrapolation, this should be interpreted with caution."
HEOR • Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology
|
|
Akira Yuasa; Hiroyuki Matsuda; Kengo Hatsuyama; Kenshi Suzuki; Marco DiBonaventura; Mitsuhiro Nagano; Patrick Hlavacek; Yoichi Kamei
|